1160924-51-5 Usage
General Description
(E)-tert-butyl 4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl)piperidine-1-carboxylate is a chemical compound that is commonly used in organic synthesis and pharmaceutical research. It is a piperidine derivative with a tert-butyl ester group, as well as a boron-containing vinyl group. The compound has the potential for use as a building block in the synthesis of various organic molecules, and it may have applications in the development of new pharmaceutical drugs or in other areas of chemical research. Its unique structure and reactivity make it a valuable tool for chemists and researchers working in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1160924-51-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,0,9,2 and 4 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1160924-51:
(9*1)+(8*1)+(7*6)+(6*0)+(5*9)+(4*2)+(3*4)+(2*5)+(1*1)=135
135 % 10 = 5
So 1160924-51-5 is a valid CAS Registry Number.
1160924-51-5Relevant articles and documents
ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE
-
Paragraph 00282; 00310-00313, (2020/08/22)
Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with an ENPP1 inhibitor compound to inhibit the cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor compound is cell impermeable. ENPP1 inhibitor compounds can act extracellularly to block the degradation of cGAMP. Also provided are pharmaceutical compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of an ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject in conjunction with administering an ENPP1 inhibitor to the subject. The radiation therapy can be administered in the subject methods at a dosage and/or frequency effective to reduce radiation damage to the subject, but still instigate an immune response.
